FR04C0028I1 - - Google Patents
Info
- Publication number
- FR04C0028I1 FR04C0028I1 FR04C0028C FR04C0028I1 FR 04C0028 I1 FR04C0028 I1 FR 04C0028I1 FR 04C0028 C FR04C0028 C FR 04C0028C FR 04C0028 I1 FR04C0028 I1 FR 04C0028I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75720596A | 1996-11-27 | 1996-11-27 | |
PCT/US1997/019041 WO1998023761A1 (en) | 1996-11-27 | 1997-10-20 | HUMANIZED ANTI-CD11a ANTIBODIES |
Publications (2)
Publication Number | Publication Date |
---|---|
FR04C0028I1 true FR04C0028I1 (nl) | 2005-02-11 |
FR04C0028I2 FR04C0028I2 (nl) | 2007-10-26 |
Family
ID=25046834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR04C0028C Active FR04C0028I2 (nl) | 1996-11-27 | 2004-12-10 |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0941344B1 (nl) |
JP (2) | JP3778945B2 (nl) |
KR (1) | KR100532178B1 (nl) |
AR (1) | AR008919A1 (nl) |
AT (1) | ATE267257T1 (nl) |
AU (1) | AU731817C (nl) |
CA (1) | CA2272842C (nl) |
DE (3) | DE122004000047I2 (nl) |
DK (2) | DK0941344T3 (nl) |
ES (1) | ES2221045T3 (nl) |
FR (1) | FR04C0028I2 (nl) |
IL (3) | IL130143A0 (nl) |
LU (1) | LU91122I2 (nl) |
NL (1) | NL300163I2 (nl) |
PT (1) | PT941344E (nl) |
WO (1) | WO1998023761A1 (nl) |
ZA (1) | ZA979599B (nl) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
SI1135498T1 (sl) | 1998-11-18 | 2008-06-30 | Genentech Inc | Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi |
AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
US6582698B1 (en) | 1999-03-19 | 2003-06-24 | Genentech, Inc. | Treatment method |
DK1163003T3 (da) * | 1999-03-19 | 2009-11-30 | Genentech Inc | Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist |
CN1409639A (zh) * | 1999-12-14 | 2003-04-09 | 杰南技术公司 | 应用TNF-α拮抗剂和LFA-1拮抗剂治疗LFA-1或TNF-α介导的疾病 |
US7575921B2 (en) | 1999-12-30 | 2009-08-18 | Vbi Technologies, L.L.C. | Spore-like cells and uses thereof |
US7560275B2 (en) | 1999-12-30 | 2009-07-14 | Vbi Technologies, L.L.C. | Compositions and methods for generating skin |
AU2001230920A1 (en) * | 2000-01-14 | 2001-07-24 | Genentech Inc. | Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1 |
ATE448306T1 (de) * | 2000-09-01 | 2009-11-15 | Blood Res Center | Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung |
US20020151050A1 (en) | 2000-10-30 | 2002-10-17 | Vacanti Charles A. | Isolation of spore-like cells from tissues exposed to extreme conditions |
DE60325334D1 (de) | 2002-02-05 | 2009-01-29 | Genentech Inc | Proteinaufreinigung |
CA2478925C (en) | 2002-04-26 | 2016-06-07 | Robert Lee Fahrner | Non-affinity purification of proteins |
ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7619070B2 (en) * | 2003-04-23 | 2009-11-17 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
PL1648940T3 (pl) | 2003-07-28 | 2016-12-30 | Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A | |
WO2005079515A2 (en) * | 2004-02-19 | 2005-09-01 | The Cbr Institute For Biomedical Research, Inc. | Conformation specific antibodies |
ATE452147T1 (de) | 2004-02-19 | 2010-01-15 | Genentech Inc | Antikörper mit korrigierten cdr |
AU2005254980A1 (en) * | 2004-06-09 | 2005-12-29 | Genentech, Inc. | Method of treating granuloma annulare or sarcoid |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
ES2374330T3 (es) | 2007-01-22 | 2012-02-15 | Genentech, Inc. | Precipitación con polielectrolito y purificación de anticuerpos. |
EP4335863A2 (en) | 2007-07-09 | 2024-03-13 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
SI2840090T1 (en) | 2007-10-30 | 2018-05-31 | Genentech, Inc. | Purification of the antibody by cation exchange chromatography |
BRPI0906550B8 (pt) * | 2008-04-09 | 2022-01-11 | Genentech Inc | Anticorpo anti-tigit, usos de um anticorpo anti-tigit e métodos in vitro para estimular a interação de cd226-pvr e/ou a interação de cd96-pvr, para aumentar ou estimular a proliferação de uma célula t ou a liberação de citocinas proinflamatórias por uma célula dendrítica, para aumentar ou estimular a resposta imune de célula t e para aumentar ou estimular a produção de citocinas proinflamatórias por uma célula dendrítica |
US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
MX2011001506A (es) | 2008-08-14 | 2011-03-15 | Genentech Inc | Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena. |
EP2684570A1 (en) | 2008-09-10 | 2014-01-15 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
CN102257122B (zh) | 2008-12-16 | 2015-07-29 | Emd密理博公司 | 搅拌槽反应器及方法 |
SG171764A1 (en) | 2008-12-16 | 2011-07-28 | Millipore Corp | Purification of proteins |
EP2400992B1 (en) | 2009-02-27 | 2015-07-22 | Genentech, Inc. | Methods and compositions for protein labelling |
MY186219A (en) | 2009-08-11 | 2021-06-30 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
CN108409829A (zh) | 2009-09-01 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 通过改进的a蛋白洗脱增强的蛋白质纯化 |
EP2499240A1 (en) | 2009-11-12 | 2012-09-19 | Vbi Technologies, LLC | Subpopulations of spore-like cells and uses thereof |
US20120309056A1 (en) | 2010-02-04 | 2012-12-06 | Leon Arnaud | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
SI2550018T1 (sl) | 2010-03-22 | 2019-05-31 | F. Hoffmann-La Roche Ag | Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine |
MX2012012743A (es) | 2010-05-03 | 2012-11-23 | Genentech Inc | Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina. |
SG184541A1 (en) | 2010-05-17 | 2012-11-29 | Emd Millipore Corp | Stimulus responsive polymers for the purification of biomolecules |
KR20190067277A (ko) | 2010-05-28 | 2019-06-14 | 제넨테크, 인크. | 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가 |
AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
JP2013537539A (ja) | 2010-08-13 | 2013-10-03 | ジェネンテック, インコーポレイテッド | 疾患の治療のためのIL−1β及びIL−18に対する抗体 |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
CN104125963B (zh) | 2011-12-22 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 使用离子交换膜层析改进下游蛋白质纯化步骤的方法 |
KR20200037425A (ko) | 2012-03-27 | 2020-04-08 | 제넨테크, 인크. | 재조합 단백질을 위한 개선된 수확 작업 |
CN104427974B (zh) | 2012-05-18 | 2018-03-23 | 基因泰克公司 | 高浓度单克隆抗体配制剂 |
US9393327B2 (en) | 2012-12-19 | 2016-07-19 | Genentech, Inc. | Methods and compositions for radiohalogen protein labeling |
SG10201710758PA (en) | 2013-07-09 | 2018-02-27 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
RU2019129525A (ru) | 2013-07-16 | 2019-11-05 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit |
NZ765734A (en) | 2014-07-09 | 2024-01-26 | Genentech Inc | Ph adjustment to improve thaw recovery of cell banks |
EP3215527A4 (en) | 2014-11-05 | 2018-04-18 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
ES2924071T3 (es) | 2015-09-02 | 2022-10-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT) |
UA124573C2 (uk) | 2015-09-25 | 2021-10-13 | Дженентек, Інк. | Антитіло, яке специфічно зв'язується з tigit людини, та спосіб лікування або сповільнення прогресування раку у суб'єкта |
WO2017091719A1 (en) | 2015-11-24 | 2017-06-01 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
CA3019373A1 (en) | 2016-03-29 | 2017-10-05 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
CN110049778A (zh) | 2016-12-22 | 2019-07-23 | 豪夫迈·罗氏有限公司 | 减少冻干多肽重构时间的方法和制剂 |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
EP4368699A2 (en) | 2018-07-03 | 2024-05-15 | Bristol-Myers Squibb Company | Methods of producing recombinant proteins |
KR20210074341A (ko) | 2018-10-10 | 2021-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법 |
AR118536A1 (es) | 2019-04-01 | 2021-10-20 | Genentech Inc | Composiciones y métodos para estabilizar formulaciones que contienen proteína |
CN113993885A (zh) | 2019-04-12 | 2022-01-28 | 格尔托公司 | 重组弹性蛋白及其生产 |
EP4007808A1 (en) | 2019-08-01 | 2022-06-08 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
WO2022066595A1 (en) | 2020-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Methods for producing therapeutic proteins |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ236792A (en) * | 1990-01-19 | 1993-05-26 | Merck & Co Inc | Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions |
US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
-
1997
- 1997-10-20 EP EP97912841A patent/EP0941344B1/en not_active Expired - Lifetime
- 1997-10-20 DK DK97912841T patent/DK0941344T3/da active
- 1997-10-20 DK DK04004941.3T patent/DK1516629T3/da active
- 1997-10-20 KR KR10-1999-7004671A patent/KR100532178B1/ko not_active IP Right Cessation
- 1997-10-20 EP EP04004941A patent/EP1516629B1/en not_active Expired - Lifetime
- 1997-10-20 PT PT97912841T patent/PT941344E/pt unknown
- 1997-10-20 IL IL13014397A patent/IL130143A0/xx active IP Right Grant
- 1997-10-20 ES ES97912841T patent/ES2221045T3/es not_active Expired - Lifetime
- 1997-10-20 CA CA2272842A patent/CA2272842C/en not_active Expired - Lifetime
- 1997-10-20 DE DE1997629209 patent/DE122004000047I2/de active Active
- 1997-10-20 DE DE200412000047 patent/DE122004000047I1/de active Pending
- 1997-10-20 AT AT97912841T patent/ATE267257T1/de active
- 1997-10-20 JP JP52464598A patent/JP3778945B2/ja not_active Expired - Lifetime
- 1997-10-20 WO PCT/US1997/019041 patent/WO1998023761A1/en not_active Application Discontinuation
- 1997-10-20 DE DE69729209T patent/DE69729209T2/de not_active Expired - Lifetime
- 1997-10-20 AU AU49929/97A patent/AU731817C/en not_active Expired
- 1997-10-27 ZA ZA979599A patent/ZA979599B/xx unknown
- 1997-11-04 AR ARP970105146A patent/AR008919A1/es active IP Right Grant
-
1999
- 1999-05-26 IL IL130143A patent/IL130143A/en not_active IP Right Cessation
-
2004
- 2004-11-10 LU LU91122C patent/LU91122I2/fr unknown
- 2004-11-12 NL NL300163C patent/NL300163I2/nl unknown
- 2004-12-10 FR FR04C0028C patent/FR04C0028I2/fr active Active
-
2005
- 2005-08-02 JP JP2005224609A patent/JP4309383B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-11 IL IL175583A patent/IL175583A0/en not_active IP Right Cessation